53BA607F-7939-40D9-BEFA-DC4ABDC7630B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.947437582128778
- age_years
- 41
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.591
- TGF_BETA_SIGNALING+0.450
- MITOTIC_SPINDLE+0.405
- MYC_TARGETS_V2+0.379
- G2M_CHECKPOINT+0.371
- PROTEIN_SECRETION+0.371
- WNT_BETA_CATENIN_SIGNALING+0.352
- UNFOLDED_PROTEIN_RESPONSE+0.335
- MYC_TARGETS_V1+0.334
- E2F_TARGETS+0.330
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.400
- KRAS_SIGNALING_DN-0.388
- SPERMATOGENESIS-0.280
- APICAL_SURFACE-0.225
- MYOGENESIS-0.197
- COAGULATION-0.148
- ANGIOGENESIS-0.137
- ALLOGRAFT_REJECTION-0.098
- HYPOXIA-0.077
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.056
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4099642A-F8D6-428C-AA12-1E76C27BB368 | — | — | 0.938 |
| 2 | F90967A5-96C6-4669-BCFB-0C51F539B0E7 | — | — | 0.917 |
| 3 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.906 |
| 4 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.905 |
| 5 | 0A7A28BA-9D46-4D4F-A0A5-B3F9AA8DF29B | — | — | 0.904 |
| 6 | E9D4A83F-EADA-4330-911A-8F02393E0BA3 | — | — | 0.903 |
| 7 | F35F85A8-B3CD-4116-990F-94B2E432F902 | — | — | 0.896 |
| 8 | SRR934870 | — | — | 0.896 |
| 9 | AE32CA37-A422-42E3-AA29-0149CF1A3019 | — | — | 0.896 |
| 10 | SRR934863 | — | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.591 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.405 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.379 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.371 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.371 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.352 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.335 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.334 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.324 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.302 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.286 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.205 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.188 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.179 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.178 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.164 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.149 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.148 | Idelalisib | — uncovered |